GCG and type 1 diabetes mellitus: Exenatide: The MAG1C RCT investigated the effects of the short-acting GLP1-RA exenatide, administered three times daily over a period of 26 weeks in 108 individuals with T1D who were randomly assigned to receive either exenatide or placebo.